References
- Hale G, Jacobs P, Wood L et al. CD52 antibodies for pre- vention of graft versus host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 2000;26:69–76.
- Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAM-PATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000;96:2419–25.
- Hale G, Cobbold S, Novitzky N et al. CAMPATH-1 anti-bodies in stem-cell transplantation. Cytotherapy 2001;3:145–64.
- Hale G, Waldmann H, for CAMPATH users. CAMPAT H-1 monoclonal antibodies in bone marrow transplantation. Hematotherapy 1994;3:15–31.
- Cull G, Haynes AP, Byrne JL et al. Preliminary experience of allogeneic stem cell transplantation for lymphoprolifera-tive disease using BEAM-CAMPATH conditioning an effective regimen with low procedure related toxicity. Br .7 Haematol 2000;108:754–60.
- Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988;322:323–7.
- Cwynarski K, Rebello P, Eades A et al. Serum levels of CAMPATH-1H in recipients of unrelated bone marrow transplants. Blood 1999;94(Suppl 1):366b.
- Craddock C, Szydlo RM, Dazzi F et al. CMV serostatus is a major determinant of outcome after T depleted unrelated donor transplant in patients with chronic myeloid leukaemia; the case for tailored GVHD prophylaxis. Br Haematol 2000;112:228–36.
- Hale G, Bright S, Chumbley G et al. Removal of T cells from bone marrow for transplantation: a monoclonal anti-lymphocyte antibody that fixes human complement. Blood 1983;62:873–82.
- Hale G. Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol- anchored glycoprotein. Immunotechnology 1995;1:175–87.
- Phillips J, Drumm A, Harrison P et al. Manufacture and quality control of CAMPATH-1 antibodies for clinical trials. Cytotherapy 2001:3:233–42.
- Spencer A, Szydlo RM, Brookes PA et al. Bone marrow transplantation for chronic myeloid leukaemia with volun-teer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA Class I identity between donor and recipient. Blood 1995;86:3590–7.
- Theobald M, Hoffmann T, Bunjes D, Heit W. Comparative analysis of in vivo T cell depletion with radiotherapy, com-bination chemotherapy and the monoclonal antibody CAMPATH-1G using limiting dilution methodology. Transplantation 1990;49:553–9.
- More11 A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. 7 Clin Invest 1970;49: 673–80.
- Kovarkit JM, Moore R, Wolf P et al. Screening for basilix-imab exposure-response relationships in renal allotransplantation. Clin Transplant 1999;13:32–8.
- Iacona I, Lazzarino M, Avanzini MA et al. Rituximab (IDEC-C2B8): Validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Ther Drug Monitor 2000;22:295–301.
- Davison GM, Novitzky N, Kline A et al. Immune reconsti-tution after allogeneic bone marrow transplantation depleted of T cells. Transplantation 2000:69:1341–7.
- Calne R, Moffatt SD, Friend PJ et al. CAMPATH-1H allows low-dose cyclosporin monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999;68:1613–16.